KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Interest Expenses (2018 - 2026)

Neogenomics filings provide 13 years of Interest Expenses readings, the most recent being $598000.0 for Q1 2026.

  • On a quarterly basis, Interest Expenses fell 63.04% to $598000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.7 million, a 58.27% decrease, with the full-year FY2025 number at $3.8 million, down 43.28% from a year prior.
  • Interest Expenses hit $598000.0 in Q1 2026 for Neogenomics, roughly flat from $599000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $5.2 million in Q4 2022 to a low of $139000.0 in Q3 2022.
  • Median Interest Expenses over the past 5 years was $1.6 million (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Interest Expenses: tumbled 89.27% in 2022 and later soared 1112.23% in 2023.
  • Neogenomics' Interest Expenses stood at $5.2 million in 2022, then tumbled by 67.77% to $1.7 million in 2023, then fell by 3.39% to $1.6 million in 2024, then tumbled by 63.12% to $599000.0 in 2025, then fell by 0.17% to $598000.0 in 2026.
  • The last three reported values for Interest Expenses were $598000.0 (Q1 2026), $599000.0 (Q4 2025), and $603000.0 (Q3 2025) per Business Quant data.